EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance

Heng Lin, Kole Tison, Yuheng Du, Paul Kirchhoff, Chan Kim, Weichao Wang, Hannah Yang, Michael Pitter, Jiali Yu, Peng Liao, Jiajia Zhou, Linda Vatan und 13 weitere

Cancer Cell · 2024-12 · 42 (12) · 2032-2044.e6

DOI: 10.1016/j.ccell.2024.10.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-12. Verfasst von Heng Lin und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, Unive…. Hauptthemen laut MEDLINE: Ferroptosis, Tumor Microenvironment, NF-E2-Related Factor 2, Succinates. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Welch Foundation, University of Michigan Medical Center Rogel Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) triggers tumor ferroptosis. However, most patients are unresponsive to ICB. Tumors might evade ferroptosis in the tumor microenvironment (TME). Here, we discover SLC13A3 is an itaconate transporter in tumor cells and endows tumor ferroptosis resistance, diminishing tumor immunity and ICB efficacy. Mechanistically, tumor cells uptake itaconate via SLC13A3 from tumor-associated macrophages (TAMs), thereby activating the NRF2-SLC7A11 pathway and escaping from immune-mediated ferroptosis. Structural modeling and molecular docking analysis identify a functional inhibitor for SLC13A3 (SLC13A3i). Deletion of ACOD1 (an essential enzyme for itaconate synthesis) in macrophages, genetic ablation of SLC13A3 in tumors, or treatment with SLC13A3i sensitize tumors to ferroptosis, curb tumor progression, and bolster ICB effectiveness. Thus, we identify the interplay between tumors and TAMs via the SLC13A3-itaconate-NRF2-SLC7A11 axis as a previously unknown immune ferroptosis resistant mechanism in the TME and SLC13A3 as a promising immunometabolic target for treating SLC13A3+ cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisTumor MicroenvironmentNF-E2-Related Factor 2SuccinatesAnimalsHumansMiceCell Line, TumorTumor-Associated MacrophagesAmino Acid Transport System y+Mice, Inbred C57BLNeoplasmsFemaleCarboxy-LyasesHydro-Lyases

Stichwörter der Autor:innen

NRF2SLC13A3SLC13A3 inhibitorSLC7A11T cell immunityferroptosisimmune checkpoint blockadeitaconatemacrophagestumor

Substanzen

NF-E2-Related Factor 2Succinatesitaconic acidSLC7A11 protein, humanAmino Acid Transport System y+NFE2L2 protein, humanACOD1 protein, humanAcod1 protein, mouseCarboxy-LyasesHydro-Lyases

Autor:innen und Institutionen

  • Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
  • Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Graduate Pr…
  • Department of Computational Medicine & Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department…
  • Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA.

Förderung

  • NCI NIH HHS
  • Welch Foundation
  • University of Michigan Medical Center Rogel Cancer Center
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Lin, H., Tison, K., Du, Y., Kirchhoff, P., Kim, C., Wang, W., Yang, H., Pitter, M., Yu, J., Liao, P., Zhou, J., Vatan, L., Grove, S., Wei, S., Vigil, T., Shah, Y. M., Mortensen, R., Kryczek, I., Garmire, L., …, & Zou, W. (2024). Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer Cell, 42(12), 2032-2044.e6. https://doi.org/10.1016/j.ccell.2024.10.010

Vancouver

Lin H, Tison K, Du Y, Kirchhoff P, Kim C, Wang W, et al. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer Cell. 2024;42(12):2032-2044.e6. doi:10.1016/j.ccell.2024.10.010

BibTeX
@article{Lin2024,
  author = {Lin, Heng and Tison, Kole and Du, Yuheng and Kirchhoff, Paul and Kim, Chan and Wang, Weichao and Yang, Hannah and Pitter, Michael and Yu, Jiali and Liao, Peng and Zhou, Jiajia and Vatan, Linda and Grove, Sara and Wei, Shuang and Vigil, Thomas and Shah, Yatrik M and Mortensen, Richard and Kryczek, Ilona and Garmire, Lana and Sivaccumar, Jwala P and Ramesh, Ashwin Kumar and Zhang, Ningyan and An, Zhiqiang and Wang, Shaomeng and Zou, Weiping},
  title = {Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {12},
  pages = {2032--2044.e6},
  doi = {10.1016/j.ccell.2024.10.010}
}
Kostenlos starten →